{"data":[{"accessionNo":"0001957912-26-000030","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001372514","issuerName":"KIORA PHARMACEUTICALS, INC.","ticker":"KPRX","cusip":"49721T507","securityClass":"Common Stock, $0.01 par value","eventDate":"2026-09-10","reportingPerson":"David Paolella","reportingCik":null,"personType":"HC,IN","sharesOwned":257500,"percentOfClass":5.8,"filedAt":"2026-09-17"},{"accessionNo":"0001957912-26-000030","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001372514","issuerName":"KIORA PHARMACEUTICALS, INC.","ticker":"KPRX","cusip":"49721T507","securityClass":"Common Stock, $0.01 par value","eventDate":"2026-09-10","reportingPerson":"Baselake Management, LLC","reportingCik":null,"personType":"IA,OO","sharesOwned":257500,"percentOfClass":5.8,"filedAt":"2026-09-17"},{"accessionNo":"0001957912-26-000030","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001372514","issuerName":"KIORA PHARMACEUTICALS, INC.","ticker":"KPRX","cusip":"49721T507","securityClass":"Common Stock, $0.01 par value","eventDate":"2026-09-10","reportingPerson":"Baselake Partners, LP","reportingCik":null,"personType":"PN","sharesOwned":257500,"percentOfClass":5.8,"filedAt":"2026-09-17"},{"accessionNo":"0001104659-26-097279","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001372514","issuerName":"KIORA PHARMACEUTICALS, INC.","ticker":"KPRX","cusip":"49721T507","securityClass":"Common Stock, $0.01 par value","eventDate":"2026-06-30","reportingPerson":"Daniel Mack","reportingCik":null,"personType":"HC","sharesOwned":491889,"percentOfClass":9.99,"filedAt":"2026-08-14"},{"accessionNo":"0001104659-26-097279","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001372514","issuerName":"KIORA PHARMACEUTICALS, INC.","ticker":"KPRX","cusip":"49721T507","securityClass":"Common Stock, $0.01 par value","eventDate":"2026-06-30","reportingPerson":"Nantahala Capital Management, LLC","reportingCik":null,"personType":"IA","sharesOwned":491889,"percentOfClass":9.99,"filedAt":"2026-08-14"},{"accessionNo":"0001104659-26-097279","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001372514","issuerName":"KIORA PHARMACEUTICALS, INC.","ticker":"KPRX","cusip":"49721T507","securityClass":"Common Stock, $0.01 par value","eventDate":"2026-06-30","reportingPerson":"Wilmot B. Harkey","reportingCik":null,"personType":"HC","sharesOwned":491889,"percentOfClass":9.99,"filedAt":"2026-08-14"},{"accessionNo":"0001104659-26-097323","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001372514","issuerName":"Kiora Pharmaceuticals, Inc.","ticker":"KPRX","cusip":"49721T507","securityClass":"Common Stock, par value $0.01 per share","eventDate":"2026-06-30","reportingPerson":"ADAR1 Capital Management, LLC","reportingCik":null,"personType":"IA,OO","sharesOwned":472721,"percentOfClass":9.9,"filedAt":"2026-08-14"},{"accessionNo":"0001104659-26-097323","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001372514","issuerName":"Kiora Pharmaceuticals, Inc.","ticker":"KPRX","cusip":"49721T507","securityClass":"Common Stock, par value $0.01 per share","eventDate":"2026-06-30","reportingPerson":"ADAR1 Capital Management GP, LLC","reportingCik":null,"personType":"OO","sharesOwned":475378,"percentOfClass":9.9,"filedAt":"2026-08-14"},{"accessionNo":"0001104659-26-097323","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001372514","issuerName":"Kiora Pharmaceuticals, Inc.","ticker":"KPRX","cusip":"49721T507","securityClass":"Common Stock, par value $0.01 per share","eventDate":"2026-06-30","reportingPerson":"Daniel Schneeberger","reportingCik":null,"personType":"HC,IN","sharesOwned":472721,"percentOfClass":9.9,"filedAt":"2026-08-14"},{"accessionNo":"0001193125-26-341731","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001372514","issuerName":"KIORA PHARMACEUTICALS, INC.","ticker":"KPRX","cusip":"49721T507","securityClass":"Common Stock, $0.01 par value","eventDate":"2026-04-06","reportingPerson":"Perceptive Advisors LLC","reportingCik":null,"personType":"IA","sharesOwned":442387,"percentOfClass":9.99,"filedAt":"2026-08-10"},{"accessionNo":"0001193125-26-341731","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001372514","issuerName":"KIORA PHARMACEUTICALS, INC.","ticker":"KPRX","cusip":"49721T507","securityClass":"Common Stock, $0.01 par value","eventDate":"2026-04-06","reportingPerson":"Joseph Edelman","reportingCik":null,"personType":"IN","sharesOwned":442387,"percentOfClass":9.99,"filedAt":"2026-08-10"},{"accessionNo":"0001193125-26-341731","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001372514","issuerName":"KIORA PHARMACEUTICALS, INC.","ticker":"KPRX","cusip":"49721T507","securityClass":"Common Stock, $0.01 par value","eventDate":"2026-04-06","reportingPerson":"Perceptive Life Sciences Master Fund, Ltd.","reportingCik":null,"personType":"CO","sharesOwned":442387,"percentOfClass":9.99,"filedAt":"2026-08-10"},{"accessionNo":"0001104659-26-062696","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001372514","issuerName":"KIORA PHARMACEUTICALS, INC.","ticker":"KPRX","cusip":"49721T507","securityClass":"Common Stock, $0.01 par value","eventDate":"2026-03-31","reportingPerson":"Wilmot B. Harkey","reportingCik":null,"personType":"HC","sharesOwned":438469,"percentOfClass":9.99,"filedAt":"2026-05-15"},{"accessionNo":"0001104659-26-062696","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001372514","issuerName":"KIORA PHARMACEUTICALS, INC.","ticker":"KPRX","cusip":"49721T507","securityClass":"Common Stock, $0.01 par value","eventDate":"2026-03-31","reportingPerson":"Daniel Mack","reportingCik":null,"personType":"HC","sharesOwned":438469,"percentOfClass":9.99,"filedAt":"2026-05-15"},{"accessionNo":"0001172661-26-002365","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001372514","issuerName":"KIORA PHARMACEUTICALS, INC.","ticker":"KPRX","cusip":"49721T507","securityClass":"Common Stock, $0.01 par value","eventDate":"2026-03-31","reportingPerson":"Alyeska Investment Group, L.P.","reportingCik":null,"personType":"IA","sharesOwned":394668,"percentOfClass":9.99,"filedAt":"2026-05-15"},{"accessionNo":"0001172661-26-002365","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001372514","issuerName":"KIORA PHARMACEUTICALS, INC.","ticker":"KPRX","cusip":"49721T507","securityClass":"Common Stock, $0.01 par value","eventDate":"2026-03-31","reportingPerson":"Alyeska Fund GP, LLC","reportingCik":null,"personType":"OO","sharesOwned":394668,"percentOfClass":9.99,"filedAt":"2026-05-15"},{"accessionNo":"0001172661-26-002365","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001372514","issuerName":"KIORA PHARMACEUTICALS, INC.","ticker":"KPRX","cusip":"49721T507","securityClass":"Common Stock, $0.01 par value","eventDate":"2026-03-31","reportingPerson":"Anand Parekh","reportingCik":null,"personType":"IN","sharesOwned":394668,"percentOfClass":9.99,"filedAt":"2026-05-15"},{"accessionNo":"0001104659-26-062696","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001372514","issuerName":"KIORA PHARMACEUTICALS, INC.","ticker":"KPRX","cusip":"49721T507","securityClass":"Common Stock, $0.01 par value","eventDate":"2026-03-31","reportingPerson":"Nantahala Capital Management, LLC","reportingCik":null,"personType":"IA","sharesOwned":438469,"percentOfClass":9.99,"filedAt":"2026-05-15"},{"accessionNo":"0001104659-26-062628","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001372514","issuerName":"KIORA PHARMACEUTICALS, INC.","ticker":"KPRX","cusip":"49721T507","securityClass":"Common Stock, $0.01 par value","eventDate":"2026-03-31","reportingPerson":"NANTAHALA CAPITAL PARTNERS LIMITED PARTNERSHIP","reportingCik":null,"personType":"PN","sharesOwned":148736,"percentOfClass":3.388,"filedAt":"2026-05-15"},{"accessionNo":"0001622627-26-000010","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001372514","issuerName":"KIORA PHARMACEUTICALS INC","ticker":"KPRX","cusip":null,"securityClass":"Common Shares","eventDate":"2025-12-31","reportingPerson":"Rosalind Advisors, Inc.","reportingCik":null,"personType":"CO","sharesOwned":464676,"percentOfClass":9.9,"filedAt":"2026-02-11"},{"accessionNo":"0001622627-26-000010","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001372514","issuerName":"KIORA PHARMACEUTICALS INC","ticker":"KPRX","cusip":null,"securityClass":"Common Shares","eventDate":"2025-12-31","reportingPerson":"SALAMON STEVEN A J","reportingCik":null,"personType":"IN","sharesOwned":464676,"percentOfClass":9.9,"filedAt":"2026-02-11"},{"accessionNo":"0001622627-26-000010","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001372514","issuerName":"KIORA PHARMACEUTICALS INC","ticker":"KPRX","cusip":null,"securityClass":"Common Shares","eventDate":"2025-12-31","reportingPerson":"Aharon Gil","reportingCik":null,"personType":"IN","sharesOwned":464676,"percentOfClass":9.9,"filedAt":"2026-02-11"},{"accessionNo":"0001622627-26-000010","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001372514","issuerName":"KIORA PHARMACEUTICALS INC","ticker":"KPRX","cusip":null,"securityClass":"Common Shares","eventDate":"2025-12-31","reportingPerson":"Rosalind Master Fund L.P.","reportingCik":null,"personType":"PN","sharesOwned":464676,"percentOfClass":9.9,"filedAt":"2026-02-11"},{"accessionNo":"0001493152-26-004296","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001372514","issuerName":"Kiora Pharmaceuticals, Inc.","ticker":"KPRX","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2025-12-31","reportingPerson":"Orin Hirschman","reportingCik":null,"personType":"HC,IN","sharesOwned":192984,"percentOfClass":4.9,"filedAt":"2026-01-29"},{"accessionNo":"0001493152-26-004296","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001372514","issuerName":"Kiora Pharmaceuticals, Inc.","ticker":"KPRX","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2025-12-31","reportingPerson":"AIGH Capital Management LLC","reportingCik":null,"personType":"IA,OO","sharesOwned":192984,"percentOfClass":4.9,"filedAt":"2026-01-29"},{"accessionNo":"0001104659-25-112617","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001372514","issuerName":"KIORA PHARMACEUTICALS, INC.","ticker":"KPRX","cusip":null,"securityClass":"Common Stock, $0.01 par value","eventDate":"2025-09-30","reportingPerson":"Daniel Mack","reportingCik":null,"personType":"HC","sharesOwned":363712,"percentOfClass":9.99,"filedAt":"2025-11-14"},{"accessionNo":"0001104659-25-112617","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001372514","issuerName":"KIORA PHARMACEUTICALS, INC.","ticker":"KPRX","cusip":null,"securityClass":"Common Stock, $0.01 par value","eventDate":"2025-09-30","reportingPerson":"Wilmot B. Harkey","reportingCik":null,"personType":"HC","sharesOwned":363712,"percentOfClass":9.99,"filedAt":"2025-11-14"},{"accessionNo":"0001104659-25-112617","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001372514","issuerName":"KIORA PHARMACEUTICALS, INC.","ticker":"KPRX","cusip":null,"securityClass":"Common Stock, $0.01 par value","eventDate":"2025-09-30","reportingPerson":"Nantahala Capital Management, LLC","reportingCik":null,"personType":"IA","sharesOwned":363712,"percentOfClass":9.99,"filedAt":"2025-11-14"}],"updatedAt":"2026-09-19T01:16:56.494Z","source":"xoomar.com","docs":"https://xoomar.com/markets/api","license":"https://xoomar.com/terms","attribution":"Credit XOOMAR with a link to the dataset page on xoomar.com when you republish this data"}